4.10.18.3Vertical
Neurology & Multiple Sclerosis Infusion
Infusion centers delivering neurological disease-modifying biologics and IV therapies.
Market snapshot
These figures describe Outpatient Infusion Centers (4.10.18), the segment that Neurology & Multiple Sclerosis Infusion sits within — not Neurology & Multiple Sclerosis Infusion on its own.
- Market size
- ~$70B
- Growth
- ~5.4%CAGR (2017–22, nominal)
- Companies
- ~21,000
FragmentationConsolidatingEstimate
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 621498 (All Other Outpatient Care Centers) — a broad category beyond infusion alone.
Business model & economics
Revenue model
Drug margin plus infusion-service reimbursement
Key economics
- Recurring revenue
- High
- EBITDA margin
- Drug-margin- and site-of-care-driven
- Capex intensity
- Moderate
recurring chronic infusion
Characteristics
- Site-of-care shift to lower-cost freestanding infusion.
- Biologics and specialty infusibles drive growth.
- Often an ancillary attached to specialty practices.
M&A deal context
Deal activityHigh
Who’s acquiring
- Infusion & specialty-care platforms
- Specialty MSO acquirers
- PE-backed consolidators
What’s driving deals
- Site-of-care shift to lower-cost infusion.
- Biologics and specialty-drug growth.
- Ancillary-driven specialty-practice consolidation.
Find Neurology & Multiple Sclerosis Infusion acquisition targets
Search Acquisera’s index for companies classified under Neurology & Multiple Sclerosis Infusion (4.10.18.3) and build a targeted deal pipeline.
Search companies